TMCI

Treace Medical Concepts Inc

Add to Watchlist

Advanced Chart

5.700

-0.09(-1.554%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

5.975

Open

5.830

VWAP

5.71

Vol

246.36K

Mkt Cap

358.56M

Low

5.645

Amount

1.41M

EV/EBITDA(TTM)

Total Shares

62.01M

335.89M

EV/OCF(TTM)

P/S(TTM)

1.69

Treace Medical Concepts, Inc. is a medical technology company. It is advancing the standard of care for the surgical management of bunion and related midfoot deformities. It has patented the Lapiplasty 3D Bunion Correction System a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. It has Adductoplasty Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, the SpeedMTP Rapid Compression Implant for addressing bunions through big toe joint fusions, and two systems for minimally invasive osteotomy surgeries: the Nanoplasty 3D Minimally Invasive Bunion Correction System and the Percuplasty Percutaneous 3D Bunion Correction System. It sells its products to physicians, surgeons, ambulatory surgery centers, hospitals, and stocking distributors.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

77.60M

+12.94%

49.85M

+10.57%

47.08M

+5.9%

Estimates Revision

The market is revising Downward the revenue expectations for Treace Medical Concepts, Inc. (TMCI) for FY2025, with the revenue forecasts being adjusted by -0.22% over the past three months. During the same period, the stock price has changed by -17.39%.

Revenue Estimates for FY2025

Revise Downward

-0.22%

In Past 3 Month

Stock Price

Go Down

-17.39%

In Past 3 Month

7 Analyst Rating

81.58% Upside

Wall Street analysts forecast TMCI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TMCI is 10.35 USD with a low forecast of 8.60 USD and a high forecast of 14.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

5 Hold

0 Sell

Moderate Buy

81.58% Upside

Current: 5.700

Low

8.60

Averages

10.35

High

14.50

81.58% Upside

Current: 5.700

Low

8.60

Averages

10.35

High

14.50

UBS

Neutral

downgrade

$10

2025-05-09

Reason

UBS

Price Target

$10

2025-05-09

downgrade

Neutral

Reason

UBS lowered the firm's price target on Treace Medical to $8.60 from $10 and keeps a Neutral rating on the shares.

Truist Securities

Richard Newitter

Hold

Maintains

$9.5 → $8

2025-04-11

Reason

Truist Securities

Richard Newitter

Price Target

$9.5 → $8

2025-04-11

Maintains

Hold

Reason

Truist lowered the firm's price target on Treace Medical to $8 from $9.50 and keeps a Hold rating on the shares as part of a broad research note previewing Q1 results in Medical Technology. The group's revenue and earnings are less at risk than it could be for a number of other sub-sectors, which will likely keep investors relatively interested in the space even with some tariff choppiness in the backdrop, though the firm is also bracing for cautious 2025 outlooks as companies and models will likely begin to dial-in some macro uncertainty, the analyst tells investors in a research note.

Truist Securities

Richard Newitter

Hold

Maintains

$10 → $9.5

2025-03-13

Reason

Truist Securities

Richard Newitter

Price Target

$10 → $9.5

2025-03-13

Maintains

Hold

Reason

Truist lowered the firm's price target on Treace Medical to $9.50 from $10 and keeps a Hold rating on the shares after its recent non-deal roadshow with CEO John Treace. Discussions mostly centered on Lapiplasty competition and new MIS Osteotomy launches, which - along with higher Lapiplasty reimbursement - should allow revenue growth to re-accelerate back to 10% ore more in Q2-Q4, the analyst tells investors in a research note. The firm remains on hold however pending greater confidence that new rollouts can sustain double-digit growth beyond easy 2025 comps, Truist adds.

Truist Securities

Richard Newitter

Hold

Maintains

$8.4 → $10

2025-03-03

Reason

Truist Securities

Richard Newitter

Price Target

$8.4 → $10

2025-03-03

Maintains

Hold

Reason

Lake Street

Ben Haynor

Strong Buy

Initiates

$15

2024-12-31

Reason

Lake Street

Ben Haynor

Price Target

$15

2024-12-31

Initiates

Strong Buy

Reason

Truist Securities

Richard Newitter

Hold

Maintains

$7 → $8.4

2024-12-18

Reason

Truist Securities

Richard Newitter

Price Target

$7 → $8.4

2024-12-18

Maintains

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Treace Medical Concepts Inc (TMCI.O) is -7.35, compared to its 5-year average forward P/E of -33.76. For a more detailed relative valuation and DCF analysis to assess Treace Medical Concepts Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-33.76

Current PE

-7.35

Overvalued PE

0.71

Undervalued PE

-68.22

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

37.66

Current EV/EBITDA

203.12

Overvalued EV/EBITDA

553.96

Undervalued EV/EBITDA

-478.64

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

6.13

Current PS

1.65

Overvalued PS

10.13

Undervalued PS

2.13

Financials

Annual

Quarterly

FY2025Q1

YoY :

+2.86%

52.57M

Total Revenue

FY2025Q1

YoY :

-17.85%

-15.58M

Operating Profit

FY2025Q1

YoY :

-14.75%

-15.92M

Net Income after Tax

FY2025Q1

YoY :

-16.67%

-0.25

EPS - Diluted

FY2025Q1

YoY :

-105.88%

655.00K

Free Cash Flow

FY2025Q1

YoY :

-0.62%

79.69

Gross Profit Margin - %

FY2025Q1

YoY :

-10.61%

-17.53

FCF Margin - %

FY2025Q1

YoY :

-17.10%

-30.29

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

398.5K

USD

6-9

Months

1.0M

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

524.1K

USD

Months

6-9

0.0

USD

Months

0-12

1.3M

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

398.5K

USD

6-9

Months

1.0M

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

524.1K

USD

Months

6-9

0.0

USD

Months

0-12

1.3M

USD

Months

TMCI News & Events

Events Timeline

2025-06-05 (ET)

2025-06-05

13:01:25

Treace Medical files patent infringement suit against Zimmer Biomet

2025-05-08 (ET)

2025-05-08

16:13:38

Treace Medical sees Q2 revenue $224M-$230M, consensus $227.53M

2025-05-08

16:13:11

Treace Medical reports Q1 EPS (25c), consensus (30c)

News

7.0

07-23Globenewswire

Notice to Long-Term Shareholders of Centene Corporation (NYSE: CNC); DoubleVerify Holdings, Inc. (NYSE: DV); Methode Electronics, Inc. (NYSE: MEI); and Treace Medical Concepts, Inc. (NASDAQ: TMCI); Grabar Law Office is Investigating Claims on Your Behalf

7.0

07-21Globenewswire

Important Notice to Long-Term Shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR); Centene Corporation (NYSE: CNC); DoubleVerify Holdings, Inc. (NYSE: DV); and Treace Medical Concepts, Inc. (NASDAQ: TMCI); Grabar Law Office is Investigating Claims on Your Behalf

7.0

07-18Globenewswire

Important Notice to Long-Term Shareholders of Centene Corporation (NYSE: CNC); DoubleVerify Holdings, Inc. (NYSE: DV); Napco Security Technologies, Inc, (NASDAQ: NSSC); and Treace Medical Concepts, Inc. (NASDAQ: TMCI); Grabar Law Office is Investigating Claims on Your Behalf